Alkermes plc's drug ALKS7290 demonstrated significant improvement in ADHD symptoms in a Phase 1b trial, with patients showing a 14- to 19-point gain on a 54-point scale within two weeks. This outperforms typical placebo effects, which range from 6 to 14 points over six to eight weeks. Analysts from Cowen & Co. and RBC Capital Markets praised the results, leading to a 2.3% rise in Alkermes' stock price. The drug, an orexin 2 receptor agonist, could expand Alkermes' treatment portfolio beyond sleep disorders into ADHD, indicating promising growth potential.
Alkermes' ALKS7290 drug trial news is presented with Pluang's Health sector market data as of Sep 21, 2026 22:32 WIB: Among 95 priced Health-sector US stocks tradable on Pluang, 52 rose and 41 fell today. Notable movers include AMPH at USD 25.23 with a +6.82% change and a typical hold time of 17 days, SMMT at USD 16.82 down -5.77%, and ACB at USD 4.01 up +3.75%.
Morgan Stanley upgraded NNN REIT from Neutral to Overweight due to its stable income and strong financial health. The REIT boasts a 99.1% occupancy rate and 97.5% fixed-rate debt, ensuring steady rental income and protection against interest rate hik...
On September 21, 2026, Sandisk was added to the S&P 100 index, replacing Nike, which was removed on the same day. This change reflects shifts in market capitalization and company performance within the index. The update is significant for investors t...
Several top analysts, including Cantor Fitzgerald, Guggenheim, Morgan Stanley, and BTIG Research, have raised price targets and upgraded their outlooks for ServiceNow, signaling confidence in the company's long-term growth. Despite this, the stock ha...
Nebius Group has been upgraded to a buy rating following a significant improvement in its operating margin, which nearly broke even in the second fiscal quarter after a -32% loss in the first quarter. This turnaround is attributed to capacity expansi...
U.S. investors have heavily invested in Solana, with spot Solana ETFs recording $47.62 million in net inflows on September 18, all into Bitwise’s Solana Staking ETF (BSOL). This raised total assets under management for Solana ETFs to about $1.62 bill...
